BrainStorm Q3 net loss widens to $2.7M, cash at $0.35M; advancing NurOwn Phase 3b trial

BRAINSTORM CELL THERAPEUTICS INC.

2024-Q3 EPS reported -$1.80

Cash, equivalents, restricted cash only $0.35M as of Sept 30, 2024; net loss $2.7M ($0.51/shr) vs $1.2M ($0.45) YoY.
R&D expenses fell to $1M from $3.3M; G&A to $2M from $2.7M.
Signed MOU with Pluri Inc. to manufacture NurOwn for planned Phase 3b ALS trial enrolling ~200 participants.
Phase 3b: 24-week placebo-controlled part (Part A) then 24-week open-label (Part B); primary endpoint: ALSFRS-R change at week 24.
Expanded Access data showed median survival 46.6 vs 41.1 months (p=0.0379) and consistent reductions in neurofilament light.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.